Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma

Y. Peñate, B. Hernández-Machín, L. I. Pérez-Méndez, F. Santiago, B. Rosales, O. Servitje, T. Estrach, M. Fernández-Guarino, L. Calzado, E. Acebo, F. Gallardo, A. Salar, R. Izu, P. L. Ortiz-Romero, R. M. Pujol, Ricardo Fernández-de-Misa

Research output: Contribution to journalArticleResearchpeer-review

36 Citations (Scopus)

Abstract

Background: Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients. Objectives: To evaluate the effectiveness, tolerance and adverse effects of ILR in patients with follicle centre (FCL) and marginal zone (MZL) PCBL. Methods: This was an epidemiological observational multicentre study of patients with PCBL treated with ILR. Results: Seventeen patients with MZL and 18 with FCL PCBL were included. The median number of lesions treated was two per patient. The treatment regimen used in 74% of the patients was a course of three injections in a single week at 1-month intervals. The dose per lesion and day of treatment was 10 mg in 71% of the patients. The median cumulative dose of rituximab per lesion was 60 mg (range 13-270) and per patient was 150 mg (range 20-360 mg). Complete response (CR) and partial response were achieved in 71% and 23% of patients, respectively. The median time to CR in patients who received 10 mg of ILR per lesion was 8 weeks. Similar response rates were observed in MZL and FCL. Median disease-free survival was 114.1 weeks. No parameters that significantly predicted CR were identified. Adverse reactions were recorded in 19 patients; the most frequent was localized pain at the injection site. Median follow-up was 21 months. Conclusions: Intralesional rituximab is a well-tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant. © 2012 The Authors BJD © 2012 British Association of Dermatologists 2012.
Original languageEnglish
Pages (from-to)174-179
JournalBritish Journal of Dermatology
Volume167
Issue number1
DOIs
Publication statusPublished - 1 Jul 2012

Fingerprint Dive into the research topics of 'Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma'. Together they form a unique fingerprint.

Cite this